Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme

Journal of Neuro-Oncology

Volumn 53, Issue 1, 2001, Pages 39-46

  Schneider, T ^a   Gerhards, R ^b   Kirches, E ^a   Firsching, R ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Glioblastoma; Immunization; NDV; Specific immunotherapy

Indexed keywords

TUMOR CELL VACCINE;

ACTIVE IMMUNIZATION; ARTICLE; BIOTECHNOLOGY; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; DRUG EFFECT; GLIOBLASTOMA; MULTIMODALITY CANCER THERAPY; NEWCASTLE DISEASE PARAMYXOVIRUS; SIDE EFFECT; TREATMENT OUTCOME; TUMOR CELL CULTURE; VACCINATION;

ADULT; AGED; BRAIN NEOPLASMS; CANCER VACCINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLIOBLASTOMA; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNIZATION; IMMUNOTHERAPY, ACTIVE; MALE; MIDDLE AGED; NEWCASTLE DISEASE VIRUS; TUMOR CELLS, CULTURED; VACCINATION;

EID: 0034784610     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011856406683     Document Type: Article

References (50)

1. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults
2. Chemotherapy for malignant gliomas
3. Immunotherapy of primary malignant brain tumors
4. Successful treatment of a malignant rat glioma with cytotoxic T lymphocytes
5. In vitro killing of human glioblastoma by interleukin-2-activated autologous lymphocytes
6. Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy
7. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir
8. Immunobiology of primary intracranial tumors. Part 7: Active immunization of patients with anaplastic human glioma cells: A pilot study
9. Glioblastoma multiforme: A controlled trial to assess the value of specific active immunotherapy in patients treated by radical surgery and radiotherapy
10. Immunobiology of brain tumors
11. Depressed cell mediated immunity in patients with primary intracranial tumors
12. Relationship of lymphocyte invasion and survival of brain tumor patients
13. Immunobiology of primary intracranial tumors. Part 1: Studies of the cellular and humoral general immune competence of brain-tumor patients
14. In situ characterization, clonogenic potential, and antitumor cytolytic activity of T lymphocytes infiltrating human brain cancers
15. Immunohistochemical analysis of infiltrating lymphocytes in central nervous system tumors
16. Mononuclear lymphoid populations infiltrating the microenvironment of primary CNS tumors. Characterization of cell subsets with monoclonal antibodies
17. Recent advances in immunobiology of brain tumors
18. Generation of cytotoxic immune responses during the progression of a rat glioma
19. The effect of irradiation on expression of HLA class I antigens in human brain tumors in culture
20. Suppression of anchorage-independent growth of human glioblastoma cell by major histocompatibility complex class I gene-transfection
21. Association of malignant glioma with the human leukocyte antigen, HLA-A24(9)
22. Perspectives for immunization of HLA-A1 patients carrying a malignant melanoma expressing gene MAGE-1
23. The human melanoma antigen-encoding gene, MAGE-1, is expressed by other tumour cells of neuroectodermal origin such as glioblastomas and neuroblastomas
24. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E
25. Mechanisms by which human gliomas may escape cellular immune attack
26. Modification of tumor cells by a low dose of Newcastle Disease Virus. Augmentation of the tumor-specific T cell response in the absence of an anti-viral response
27. Effect of the expression of transforming growth factor-β2 in primary human glioblastomas on immunosuppression and loss of immune surveillance
28. Peripheral immunization against malignant rat glioma can induce effective anti-tumor immunity in the brain
29. Modulation of T-cell function by gliomas
30. Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. II. Establishment of specific systemic anti-tumor immunity
31. Active specific immunotherapy - A new modality of cancer treatment involving the patient's own immune system
32. Newcastle disease virus as an anti-neoplastic agent
33. Newcastle Disease Virus as an antineoplastic agent: Induction of tumor necrosis factor-α and augmentation of its cytotoxicity
34. Interferon induction by viruses. X. A model for interferon induction by Newcastle Disease Virus
35. Postoperative activation of tumor-specific T-cells as a means to achieve immune control of minimal residual disease
36. Successful application of non oncogenic viruses for antimetastatic cancer immunotherapy
37. Modification of tumor cells by a low dose of Newcastle Disease Virus. III. Potentiation of tumor-specific cytolytic T cell activity via induction of interferon-α/β
38. Postoperative active specific immunization in colorectal cancer patients with virus-modified autologous tumor-cell vaccine. First clinical results with tumor-cell vaccines modified with live but avirulent Newcastle disease virus
39. A phase II study on the postsurgical management of stage II malignant melanoma with a Newcastle disease virus oncolysate
40. Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer
41. Adjuvant active specific immunotherapy for human colorectal cancer: 6,5-year median follow-up of a phase III prospectively randomized trial
42. Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial
43. Postoperative active specific immunotherapy with supportive measures in patients suffering from recurrent metastasized melanoma: Case report of six patients
44. The multi-test system: A standardized approach to evaluation of delayed hypersensitivity and cell-mediated immunity
45. Toxicity determined in vitro by morphological alterations and neutral red absorption
46. Immunobiology of primary intracranial tumors. Part 8: Serological responses to active immunization of patients with anaplastic gliomas
47. Natural antibody in human serum to a neoantigen in human cultured cells grown in fetal bovine serum
48. Antigenic specificities acquired from the growth medium by cells in tissue culture
49. Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor β2